Experimental drug shows promise for rare paralysis disorder in single patient trial
NCT ID NCT07542548
First seen May 24, 2026 · Last updated May 24, 2026
Summary
This study tested the drug D-cycloserine in one person with a rare genetic form of hereditary spastic paraplegia, a condition that causes muscle stiffness and movement problems. The goal was to see if the drug could safely reduce harmful fat-like substances in the body and slow down the disease. The participant was closely monitored for side effects and changes in motor function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY SPASTIC PARAPLEGIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.